Testosterone Undecanoate Patent Expiration
Testosterone Undecanoate is Used for treating conditions associated with deficiency or absence of endogenous testosterone in adult males, including primary hypogonadism and hypogonadotropic hypogonadism. It was first introduced by Endo Operations Ltd
Testosterone Undecanoate Patents
Given below is the list of patents protecting Testosterone Undecanoate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tlando | US11464735 | Fixed dose oral testosterone undecanoate compositions and use thereof | Apr 28, 2041 | Verity |
| Tlando | US12011503 | Fixed dose oral testosterone undecanoate compositions and use thereof | Oct 16, 2040 | Verity |
| Jatenzo | US11564933 | Methods of treating testosterone deficiency | Apr 12, 2039 | Tolmar |
| Tlando | US11559530 | Oral testosterone undecanoate therapy | Nov 28, 2037 | Verity |
| Kyzatrex | US11617758 | Emulsion formulations | Mar 15, 2033 | Marius Pharms Llc |
| Kyzatrex | US10576089 | Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols | Dec 31, 2030 | Marius Pharms Llc |
| Kyzatrex | US10576090 | Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols | Dec 31, 2030 | Marius Pharms Llc |
| Kyzatrex | US11590146 | Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols | Dec 31, 2030 | Marius Pharms Llc |
| Jatenzo | US8492369 | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same | Dec 20, 2030 | Tolmar |
| Tlando | US10226473 | High-strength testosterone undecanoate compositions | Nov 30, 2030 | Verity |
| Tlando | US10716794 | High-strength testosterone undecanoate compositions | Nov 30, 2030 | Verity |
| Tlando | US11311555 | High-strength testosterone undecanoate compositions | Nov 30, 2030 | Verity |
| Tlando | US11364249 | High-strength testosterone undecanoate compositions | Nov 30, 2030 | Verity |
| Tlando | US11433083 | High-strength testosterone undecanoate compositions | Nov 30, 2030 | Verity |
| Tlando | US9943527 | High-strength testosterone undecanoate compositions | Nov 30, 2030 | Verity |
| Tlando | US9949985 | High-strength testosterone undecanoate compositions | Nov 30, 2030 | Verity |
| Jatenzo | US10543219 | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same | Apr 12, 2030 | Tolmar |
| Jatenzo | US10617696 | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same | Apr 12, 2030 | Tolmar |
| Jatenzo | US11179403 | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same | Apr 12, 2030 | Tolmar |
| Jatenzo | US11426416 | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same | Apr 12, 2030 | Tolmar |
| Jatenzo | US8778916 | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same | Apr 12, 2030 | Tolmar |
| Jatenzo | US8241664 | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same | Mar 29, 2029 | Tolmar |
| Tlando | US11304960 | Steroidal compositions | Jan 08, 2029 | Verity |
| Tlando | US8778922 | Steroidal compositions | Jan 08, 2029 | Verity |
| Tlando | US8865695 | Steroidal compositions | Jan 08, 2029 | Verity |
| Aveed | US8338395 | Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels | May 08, 2027 | Endo Operations |
| Aveed | US7718640 | Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels | Mar 14, 2027 | Endo Operations |
| Jatenzo | US11331325 | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same | Jan 06, 2027 | Tolmar |
| Jatenzo | US11179402 | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same | Apr 14, 2026 | Tolmar |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Testosterone Undecanoate's patents.
Latest Legal Activities on Testosterone Undecanoate's Patents
Given below is the list recent legal activities going on the following patents of Testosterone Undecanoate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 09 Mar, 2023 | US10226473 |
| Surcharge for late Payment, Small Entity | 09 Mar, 2023 | US10226473 |
| Recordation of Patent Grant Mailed Critical | 24 Jan, 2023 | US11559530 |
| Patent Issue Date Used in PTA Calculation Critical | 24 Jan, 2023 | US11559530 |
| Correspondence Address Change Critical | 09 Jan, 2023 | US11464735 |
| Email Notification Critical | 05 Jan, 2023 | US11559530 |
| Issue Notification Mailed Critical | 04 Jan, 2023 | US11559530 |
| Mail Miscellaneous Communication to Applicant | 28 Dec, 2022 | US11559530 |
| Email Notification Critical | 28 Dec, 2022 | US11559530 |
| Miscellaneous Communication to Applicant - No Action Count | 22 Dec, 2022 | US11559530 |
Testosterone Undecanoate's Family Patents
